Dermaroller 0.5 mm

Does Microneedling Regrow Hair? What the Studies Actually Show

Microneedling has real trial evidence behind it, but that evidence supports a narrower claim than most product pages make. Across several randomised trials, adding weekly or biweekly microneedling to a minoxidil routine produced better hair counts than minoxidil alone, and a 2025 meta-analysis pooling that data agreed with the trend. The largest single trial on record, though, found no such benefit at all. No trial has tested microneedling as a way to skip minoxidil rather than support it, so the honest grade is that microneedling looks like a plausible, evidence-graded addition to a minoxidil routine, not a proven treatment in its own right, and depth and frequency matter more to the result than most guides mention.

  • The founding trial is real but small: a 2013 pilot study of 94 men found a significant hair-count advantage for microneedling plus minoxidil, but it was a single centre, 12 weeks, and never designed to be the final word.
  • Depth has a ceiling, not a floor to push past: the trial evidence favours shallow, at-home-range depths; going deeper hasn't been shown to add benefit and does add irritation risk.
  • The pooled picture leans positive but disagrees with itself: a 2025 meta-analysis of 12 trials found a significant benefit overall, with high variation between the individual trials feeding into it.
  • The largest single trial found nothing extra: 245 women followed for 24 weeks saw no measurable difference between minoxidil alone and minoxidil plus microneedling.
  • It is not risk-free: certain people should speak to a doctor before microneedling their scalp at all, and overdoing depth or frequency is where most of the risk actually sits.

What Microneedling Is Supposed to Do for Hair Loss

The idea behind scalp microneedling borrows directly from skin microneedling: a roller or pen studded with fine needles creates hundreds of controlled, shallow punctures, and the skin responds by ramping up collagen production and local blood flow as it heals. For hair loss, the theory is that this response also stimulates the follicle and, separately, opens tiny channels that let a topical treatment penetrate more effectively than it would on intact skin.

That second mechanism is why microneedling for hair loss is marketed almost entirely as something done alongside a topical minoxidil routine, not as a standalone treatment. Every major trial on the topic tests it that way, and a dermaroller's product instructions are written around the same assumption: needle, then apply minoxidil to skin that's primed to absorb it, rather than expecting the needling itself to be the active ingredient.

It's also worth separating the at-home tool from the in-office one. Professional devices used in clinics for scalp treatment carry needles meaningfully longer than a consumer dermaroller's, which is part of why an at-home routine calls for more caution around depth and frequency than a single in-clinic session might.

The Trial the Category Is Marketed On

Most of the "microneedling regrows hair" claims you'll see trace back to one study: a 2013 evaluator-blinded pilot trial that randomised 94 men with moderate androgenetic alopecia (Norwood-Hamilton grade III to IV) to either weekly 1.5 mm microneedling combined with twice-daily 5% minoxidil, or twice-daily 5% minoxidil alone, over 12 weeks.

The results were genuinely striking for a trial that size. Mean hair count increased by 91.4 in the microneedling-plus-minoxidil group against 22.2 in the minoxidil-only group, a statistically significant difference (P=.039). On the patients' own assessment, 82% of the microneedling group reported that more than half their hair loss had visibly improved, compared with 4.5% of the control group.

Those numbers explain why the category leans on this trial so heavily, but it's worth being precise about what it actually is: a single-centre, 12-week pilot study in 94 men. That's a legitimate signal worth following up, but it isn't the large, independently replicated result that "clinically proven" implies. Pages that stop at this study and call the case closed are citing the opening data point, not the full picture (source: Dhurat et al., Int J Trichology, 2013).

What Depth and How Often the Evidence Points To

Once you look past the headline trial, the more useful question for someone deciding on a routine is what depth and frequency the evidence actually supports, because "microneedling" covers a wide range of both. A 2021 trial that randomised 60 patients on minoxidil into three arms found that biweekly microneedling at 0.6 mm produced significantly greater hair-count and hair-thickness gains than minoxidil alone, while the 1.2 mm arm's advantage over minoxidil alone was smaller and less consistent. In other words, the shallower depth performed better than the deeper one, not the reverse.

A separate subgroup analysis, drawn from the pooled data of the 2025 meta-analysis discussed below, compared depths of roughly 1 mm and under against depths greater than 1 mm and found no significant difference between them. Put together, the depth evidence points the same direction from two angles: pushing past roughly 1 mm doesn't appear to buy any extra benefit, and the trial that compared depths head-to-head found the shallower one did better, not worse.

The practical read is that shorter and shallower, done consistently on a fixed schedule, is what the evidence supports, rather than going deeper or more often in the hope of a faster result. Worth flagging: the depths and frequencies tested in these trials, 1.5 mm weekly, 0.6 mm or 1.2 mm biweekly, aren't identical to the 0.5 mm weekly routine a consumer dermaroller is built around. The trials establish a direction, shallow and regular beats deep and frequent, not an exact protocol to copy at home.

Pooling the Trials: What a 2025 Meta-Analysis Found

Because individual trials are small and vary in how they're designed, researchers periodically combine them into a meta-analysis to see what the aggregate picture looks like. A 2025 systematic review did exactly that, pooling 12 randomised controlled trials and 631 patients with androgenetic alopecia comparing microneedling plus minoxidil against minoxidil alone.

The pooled result favoured the combination: hair count improved significantly more with microneedling plus minoxidil than with minoxidil alone (standardised mean difference of 1.32, 95% confidence interval 0.73 to 1.92). But the analysis also reported substantial heterogeneity between the trials it combined (I²=88%), a technical way of saying the individual studies didn't agree with each other very much, so the pooled number averages a genuinely mixed set of results rather than a dozen trials converging on the same answer.

Subgroup comparisons within that same analysis found session duration and device type, an electrodynamic pen versus a manual roller, didn't significantly change the outcome either. On safety, adverse events were more frequent in the combination group than with minoxidil alone (74 events versus 59), though generally mild and self-limiting, such as scalp itching and some extra hair growth at the treated site, rather than serious complications (source: Ahmed et al., Archives of Dermatological Research, 2025).

The Largest Single Trial Disagrees

If the pooled picture were the whole story, the case for microneedling as a minoxidil add-on would look fairly settled. It isn't, because the largest individual trial on the topic found the opposite result. A 2026 randomised controlled trial followed 245 women with mild-to-moderate androgenetic alopecia for 24 weeks, comparing minoxidil alone against minoxidil combined with microneedling performed either monthly or every two weeks, using a 36-needle cartridge at a 500 to 550 micron depth.

All three groups improved from their starting point, which is expected on minoxidil regardless of anything else added to it. But the improvements were statistically indistinguishable between the groups: the microneedling arms, at either frequency, did no better than minoxidil on its own, in a trial with 234 completers, and the researchers concluded microneedling didn't provide additional clinical benefit over minoxidil alone in this population.

A single trial this size, with 234 completers and a clean three-arm design, carries real statistical weight on its own. The meta-analysis it's being weighed against is a pool of twelve much smaller, inconsistent studies, exactly the heterogeneity the 2025 review flagged in its own results. Neither cancels the other out; they represent genuinely different evidence pointing different ways, and a fair grade has to hold both at once (source: Liu et al., Journal of the American Academy of Dermatology, 2026). The honest read is that microneedling looks promising in aggregate, was contradicted by the largest individual trial run so far, and the question isn't settled either way.

Who Shouldn't Do This, and What Correct Use Looks Like

Because microneedling is a skin procedure and not a passive product, getting the technique and the candidacy right matters more here than with most items in a hair-care routine. A patient-resource review of the evidence notes that repeated, excessive microneedling can cause low-grade inflammation and micro-scarring around the follicle instead of helping it, and recommends it be performed carefully or under professional guidance (source: American Hair Loss Association).

Some people shouldn't be microneedling their scalp at home at all without speaking to a doctor first: anyone on blood thinners, anyone with a bleeding disorder, and anyone with a history of keloid scarring. The same goes for skin that's inflamed, broken, sunburnt or infected, skin over active acne, skin near the eyes, and skin over moles or raised lesions, none of which is a surface to needle.

For everyone else, the Dermaroller 0.5 mm's own instructions describe what correct use looks like in practice: once a week on a fixed day, on skin that's clean, dry and disinfected before rolling and disinfected again afterwards, with minoxidil paused for the 24 hours that follow. It shouldn't be started in the first fortnight of a new minoxidil routine, and the roller itself should be replaced every three months, since a blunted needle tears skin rather than piercing it cleanly.

Quintéa Dermaroller 0.5 mm on an oxblood handle with its protective cap
The Dermaroller 0.5 mm: the shallow, weekly routine its instructions describe reflects the depth and frequency the trial evidence favours.

So, Does Microneedling Regrow Hair?

Graded on its own, without the "adjunct" qualifier, microneedling has no trial evidence behind it at all; every study discussed here tested it alongside minoxidil, never as a replacement for it. Graded as an addition to minoxidil, the fair verdict is that it has a plausible, evidence-supported benefit that hasn't been settled: several small-to-medium trials and a pooled meta-analysis of that data lean positive, the largest single trial to date found no added benefit over minoxidil alone, and depth beyond roughly 0.6 mm doesn't appear to buy anything the trials can detect.

For a reader already using a topical minoxidil and deciding whether to add microneedling to that routine, the evidence supports trying it at a shallow depth on a consistent weekly schedule, not as a way to shorten or replace the minoxidil part of the routine. The Dermaroller's own instructions, once weekly, 0.5 mm, a 24-hour pause on minoxidil afterwards, track that evidence rather than the more dramatic claims found elsewhere. If you're weighing it against other additions, whether biotin adds anything worth the trouble and how Redensyl compares against minoxidil's own evidence base are graded the same way, and what minoxidil itself is doing is covered separately. The Ingredients & Evidence hub covers the rest of the range the same way: what's actually been studied, and what hasn't.

Back to blog